
May 14, 2026
Alzheimer’s Blood-Based Biomarker Testing Integrated into Clinical Workflows
A new partnership between Lucent Diagnostics and Tempus AI is set to enhance the integration of blood-based biomarker testing for Alzheimer’s disease into clinical practices.Lucent Diagnostics, part of Quanterix Corp, has teamed up with Tempus AI Inc to facilitate the use of multi-biomarker panels aimed at improving the accuracy of Alzheimer’s detection. This collaboration will see the development of a care gap program utilizing Tempus Next, an AI-driven platform designed to streamline the testi









